BRPI0510895A - formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t - Google Patents

formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t

Info

Publication number
BRPI0510895A
BRPI0510895A BRPI0510895-0A BRPI0510895A BRPI0510895A BR PI0510895 A BRPI0510895 A BR PI0510895A BR PI0510895 A BRPI0510895 A BR PI0510895A BR PI0510895 A BRPI0510895 A BR PI0510895A
Authority
BR
Brazil
Prior art keywords
cell lymphoma
deazaaminopterin
propargyl
pharmaceutical formulation
lymphoma treatment
Prior art date
Application number
BRPI0510895-0A
Other languages
English (en)
Inventor
Owen A O'connor
Francis Sirotnak
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0510895(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of BRPI0510895A publication Critical patent/BRPI0510895A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

FORMULAçãO FARMACêUTICA DE 10-PROPARGILA-l0-DEAZAAMINOPTERINA PARA TRATAMENTO DE LINFOMA DE CéLULA T O linfoma de célula T é tratado por meio da administração a um paciente acometido por linfoma de célula T de uma quantidade terapeuticamente eficaz de l0-proparqila-l0- deazaamino-pterina. Observa-se a remissão em pacientes humanos, mesmo com linfomas de célula T resistentes à droga em níveis de dosagem semanal tão baixos quanto 30 mg/m¬ 2¬. Em geral, a 10-propargila-l0-deazaamino-pterina é administrada numa quantidade de 30 a 275 mg/m¬ 2¬por dose.
BRPI0510895-0A 2004-05-30 2005-05-31 formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t BRPI0510895A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
PCT/US2005/019169 WO2005117891A1 (en) 2004-05-30 2005-05-31 Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Publications (1)

Publication Number Publication Date
BRPI0510895A true BRPI0510895A (pt) 2007-11-27

Family

ID=34971703

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510895-0A BRPI0510895A (pt) 2004-05-30 2005-05-31 formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t

Country Status (24)

Country Link
US (4) US7622470B2 (pt)
EP (1) EP1750716B1 (pt)
JP (1) JP5005532B2 (pt)
KR (1) KR101189693B1 (pt)
CN (2) CN102824346B (pt)
AT (1) ATE405272T1 (pt)
AU (1) AU2005249516B2 (pt)
BR (1) BRPI0510895A (pt)
CA (1) CA2565968C (pt)
DE (1) DE602005009176D1 (pt)
DK (1) DK1750716T3 (pt)
ES (1) ES2313365T3 (pt)
HK (1) HK1177901A1 (pt)
HR (1) HRP20080569T3 (pt)
ME (1) ME01087B (pt)
MX (1) MXPA06013559A (pt)
NO (1) NO337276B1 (pt)
NZ (2) NZ576849A (pt)
PL (1) PL1750716T3 (pt)
PT (1) PT1750716E (pt)
RS (1) RS50622B (pt)
SI (1) SI1750716T1 (pt)
WO (2) WO2005117891A1 (pt)
ZA (1) ZA200609266B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20080188479A1 (en) 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
US7622470B2 (en) * 2004-05-30 2009-11-24 Sloan-Kettering Institute For Cancer Research Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
US8263354B2 (en) 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20090048262A1 (en) * 2007-08-17 2009-02-19 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
KR101734152B1 (ko) 2008-07-03 2017-05-11 액세라인크 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
US20110190305A1 (en) 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
DK2575466T3 (en) * 2010-06-02 2015-07-20 Allos Therapeutics Inc Methods of treating methotrexate resistant disorders of 10-propargyl-10-deazaaminopterin
CA2807484A1 (en) * 2010-08-10 2012-02-16 Allos Therapeutics, Inc. Methods for extending progression-free survival using 10-propargyl-10-deazaaminopterin
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
US11439643B2 (en) 2015-06-16 2022-09-13 Acrotech Biopharma Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69121844T2 (de) 1990-11-20 1997-01-23 Behringwerke Ag Immunotest für Cyclosporin
US5354751A (en) 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
DK0944389T3 (da) * 1996-07-17 2008-11-17 Sloan Kettering Inst Cancer Oprensede sammensætninger af 10-propargyl-10-deazaaminopterin og fremgangsmåder til anvendelse deraf i behandlingen af tumorer
US6323205B1 (en) 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
US7622470B2 (en) * 2004-05-30 2009-11-24 Sloan-Kettering Institute For Cancer Research Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin

Also Published As

Publication number Publication date
ATE405272T1 (de) 2008-09-15
KR20110081327A (ko) 2011-07-13
JP5005532B2 (ja) 2012-08-22
NO337276B1 (no) 2016-02-29
ME01087B (me) 2012-12-20
AU2005249516B2 (en) 2010-11-18
HRP20080569T3 (en) 2008-12-31
JP2008501038A (ja) 2008-01-17
RS50622B (sr) 2010-06-30
ZA200609266B (en) 2008-12-31
PL1750716T3 (pl) 2009-01-30
MXPA06013559A (es) 2007-04-24
EP1750716A1 (en) 2007-02-14
EP1750716B1 (en) 2008-08-20
CN1960734A (zh) 2007-05-09
NZ551082A (en) 2009-06-26
NO20065971L (no) 2006-12-22
CA2565968C (en) 2013-01-08
NZ576849A (en) 2011-03-31
CA2565968A1 (en) 2005-12-15
ES2313365T3 (es) 2009-03-01
US8299078B2 (en) 2012-10-30
DE602005009176D1 (de) 2008-10-02
CN102824346B (zh) 2015-04-22
DK1750716T3 (da) 2008-12-08
US20130053391A1 (en) 2013-02-28
US20080058280A1 (en) 2008-03-06
US7622470B2 (en) 2009-11-24
WO2005117892A1 (en) 2005-12-15
CN102824346A (zh) 2012-12-19
KR101189693B1 (ko) 2012-10-10
WO2005117891A1 (en) 2005-12-15
HK1177901A1 (en) 2013-08-30
US20100120777A1 (en) 2010-05-13
US20050267117A1 (en) 2005-12-01
SI1750716T1 (sl) 2009-06-30
US7939530B2 (en) 2011-05-10
PT1750716E (pt) 2008-11-04
AU2005249516A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
RU2356547C2 (ru) Способы лечения рака с использованием ингибиторов hdac
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
PL350313A1 (en) Apomorphine and sildenafil composition
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
HK1139871A1 (en) Improvements in and relating to medicinal compositions
EA200401317A1 (ru) Композиции и способы дозирования липосом определенных размеров для лечения или предотвращения заболевания
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
MXPA05012810A (es) Formas de dosis oral de memantina.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
IL196425A (en) Dosage unit for oral administration containing ibuprofen and pamotidine
RU2015103107A (ru) Комбинированная композиция
SG146638A1 (en) Pharmaceutical delivery system
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
NZ590981A (en) Transdermal therapeutic system (TTS) for administration with a wafer
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
JP2011500589A5 (pt)
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A 3A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2158 DE 15/05/2012.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]